It will be interesting to see the final phase 1 results . With the NSCLC the industry leader appears to be DNAs Avastin in combo with paclitaxel/carboplatin.
>>Progression-free and overall survival were also significantly improved; the average progression-free survival was 6.4 months in the Avastin treatment group, compared to 4.5 months in the chemotherapy alone group. The average overall survival was 12.5 months in the Avastin group, compared to 10.2 months for the patients who received paclitaxel/carboplatin.<<
After 50 years R&D into NSCLC sadly 6.4 months TTP and 12.5 months survival is not much to beat .
SBP
solbec pharmaceuticals limited
